抗瓜氨酸化蛋白及天然蛋白抗体与类风湿关节炎相关间质性肺病预测:巢式病例对照研究
在Brigham RA序贯研究中的巢式病例对照研究纳入84例新发RA-ILD病例和233例无ILD的RA对照,检测血清中抗瓜氨酸化蛋白抗体(ACPA)及抗天然蛋白抗体。发现6种精细特异性抗体与RA-ILD相关,其预测RA-ILD的乐观校正AUC为0.84,优于所有临床因素联合的0.73。结合抗体与临床因素的风险评分在预测概率50%时特异度≥93%。
要点
- 6种精细特异性ACPA及抗天然蛋白抗体与RA-ILD风险相关。
- 这6种抗体预测RA-ILD的乐观校正AUC=0.84,优于临床因素联合的0.73。
- 结合抗体与临床因素的风险评分在预测概率50%时特异度≥93%。
核心结论
- 特定ACPA和抗天然蛋白抗体可改善RA-ILD预测,并提示滑膜蛋白抗体参与RA-ILD发病机制,一旦在外部队列验证后可能具有临床预测效用。
研究设计与样本
- Brigham RA序贯研究中的巢式病例对照研究,将新发RA-ILD病例按采血时间、年龄、性别、RA病程和类风湿因子状态匹配至RA无ILD对照。
- 采用多重检测法测定RA-ILD发病前储存血清中的ACPA和抗天然蛋白抗体,用logistic回归计算RA-ILD的OR及95%CI并调整前瞻性收集的协变量。
- 使用内部验证估计乐观校正AUC,并以模型系数生成RA-ILD风险评分。
主要发现
- 共分析84例新发RA-ILD病例(平均年龄67岁,77%女性,90%白人)和233例RA无ILD对照(平均年龄66岁,80%女性,94%白人)。
- 鉴定出6种与RA-ILD相关的精细特异性抗体:抗瓜氨酸化组蛋白4的IgA2(每log转换单位OR 0.08,95%CI 0.03-0.22)、抗瓜氨酸化组蛋白2A的IgA2(OR 4.03,95%CI 2.03-8.00)、抗环瓜氨酸化丝聚蛋白的IgG(OR 3.47,95%CI 1.71-7.01)、抗天然环化组蛋白2A的IgA2(OR 5.52,95%CI 2.38-12.78)、抗天然组蛋白2A的IgA2(OR 4.60,95%CI 2.18-9.74)、抗天然环化丝聚蛋白的IgG(OR 2.53,95%CI 1.47-4.34)。
- 这6种抗体预测RA-ILD风险优于所有临床因素联合(乐观校正AUC=0.84 vs 0.73)。
- 开发了结合这些抗体与临床因素(吸烟、疾病活动度、糖皮质激素使用、肥胖)的RA-ILD风险评分。
- 在预测RA-ILD概率50%时,无生物标志物风险评分(评分=2.6)和有生物标志物风险评分(评分=5.9)均达到RA-ILD特异度≥93%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出这些发现需在外部队列验证后才可能具有临床预测效用(原文:once validated in external studies)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To identify fine specificity anti-citrullinated protein antibodies (ACPA) associated with incident rheumatoid arthritis-associated interstitial lung disease (RA-ILD). METHODS: This nested case-control study within the Brigham RA Sequential Study matched incident RA-ILD cases to RA-noILD controls on time of blood collection, age, sex, RA duration, and rheumatoid factor status. A multiplex assay measured ACPA and anti-native protein antibodies from stored serum prior to RA-ILD onset. Logistic regression models calculated odds ratios (OR) with 95% confidence intervals (CI) for RA-ILD, adjusting for prospectively-collected covariates. We estimated optimism-corrected area under the curves (AUC) using internal validation. Model coefficients generated a risk score for RA-ILD. FINDINGS: We analyzed 84 incident RA-ILD cases (mean age 67 years, 77% female, 90% White) and 233 RA-noILD controls (mean age 66 years, 80% female, 94% White). We identified six fine specificity antibodies that were associated with RA-ILD. The antibody isotypes and targeted proteins were: IgA2 to citrullinated histone 4 (OR 0.08 per log-transformed unit, 95% CI 0.03-0.22), IgA2 to citrullinated histone 2A (OR 4.03, 95% CI 2.03-8.00), IgG to cyclic citrullinated filaggrin (OR 3.47, 95% CI 1.71-7.01), IgA2 to native cyclic histone 2A (OR 5.52, 95% CI 2.38-12.78), IgA2 to native histone 2A (OR 4.60, 95% CI 2.18-9.74), and IgG to native cyclic filaggrin (OR 2.53, 95% CI 1.47-4.34). These six antibodies predicted RA-ILD risk better than all clinical factors combined (optimism-corrected AUC=0·84 versus 0·73). We developed a risk score for RA-ILD combining these antibodies with the clinical factors (smoking, disease activity, glucocorticoid use, obesity). At 50% predicted RA-ILD probability, the risk scores both without (score=2·6) and with (score=5·9) biomarkers achieved specificity ≥93% for RA-ILD. INTERPRETATION: Specific ACPA and anti-native protein antibodies improve RA-ILD prediction. These findings implicate synovial protein antibodies in the pathogenesis of RA-ILD and suggest clinical utility in predicting RA-ILD once validated in external studies. FUNDING: National Institutes of Health.
引用
- Kronzer VL, Hayashi K, Yoshida K, et al. Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: A nested case-control study. Lancet Rheumatol. 2023. PMID: 36874209. doi:10.1016/s2665-9913(22)00380-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。